G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage

G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage

Abstract Pathogenic mutations in LRRK2 cause Parkinson’s disease (PD). The G2019S variant is the most common, which results in abnormally high kinase activity. Compounds that target LRRK2 kinase activity are currently being developed and tested in clinical trials. We recently found that G2019S LRRK2...

Full description

Bibliographic Details
Main Authors: Nicholas Pena, Tara Richbourg, Claudia P. Gonzalez-Hunt, Rui Qi, Paul Wren, Carrolee Barlow, Natalie F. Shanks, Holly J. Carlisle, Laurie H. Sanders
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:npj Parkinson's Disease
Online Access:https://doi.org/10.1038/s41531-024-00660-y

Internet

https://doi.org/10.1038/s41531-024-00660-y

Similar Items